Imbruvica (Ibrutinib) is a prescription medication used in the treatment of various types of blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and others. It is classified as a Bruton’s tyrosine kinase (BTK) inhibitor, which works by disrupting the signaling pathways that are essential for the survival and proliferation of cancer cells.
Imbruvica is indicated for the treatment of:
The recommended dose of Imbruvica is 140 mg taken orally once daily. It is important to take the medication consistently at the same time each day. Patients should swallow the tablets whole with a glass of water and avoid taking them with certain foods that may affect absorption, such as grapefruit or Seville oranges.
Common side effects of Imbruvica may include:
Serious side effects can occur, including bleeding problems, infections, and heart rhythm issues. Patients should report any unusual symptoms to their healthcare provider promptly.
Before starting Imbruvica, patients should inform their healthcare provider about any other medications they are taking, as well as any history of heart problems or bleeding disorders. Regular monitoring may be required during treatment to assess blood counts and liver function.
Imbruvica (Ibrutinib) offers a targeted therapy option for patients with specific types of blood cancers, providing an alternative to traditional chemotherapy. Always consult with a healthcare professional for personalized medical advice and treatment plans.
Prescription Required 
India
